![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 19, 2020 5:37:38 PM
I for one, am inspired by Diwan's persistence and abilities to mature NNVC's technology over the last 15 years - to the point that they likely have the only COVID19 therapeutic that attacks that virus directly, at the human cell ACE2 receptor site, and is 100% nontoxic. NNVC's anti-viral will also works whether the virus mutates or not. Its amazing what Diwan has accomplished with his small team of motivated experts.
The latest video on NNVC's progress on a COVID antiviral is so cool. The amount of info packed into this was much greater than any PR could produce. Just because NNVC paid to have the video made doesn't mean its not true. Three highly trained experts solving one of worlds most challenging health issues. Only in America.
All the lag time issues for Flu vaccines are a matter of record - not to mention that the CDC itself only expects a 50% effectiveness rate for the Flu vaccine. The 2020 flu vaccine effectiveness is estimated by the CDC to have been 45%.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6907a1.htm
Just watch how fast their anti-viral gets the fast track. Anti-viral Phase 1-2-3 trials are orders of magnitude faster than for vaccines.
Given the apparent growth factor of COVID19 is twice that of seasonal flu, not counting the 30% of the population who get infected and don't know it, - half the country, or more, will have been infected by the time the COVID19 vaccines complete Phase III.
https://www.vox.com/science-and-health/2020/4/2/21197617/coronavirus-pandemic-covid-19-death-rate-transmission-risk-factors-lockdowns-social-distancing
Everything I have learned about NNVC, viruses and the opinions of this board, for that matter, have only reinforced my belief that Diwan and NNVC have been right on target all along. We are fortunate to have a company like Nanoviricides in the US at this critical time.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM